07:21 AM EDT, 09/10/2024 (MT Newswires) -- Silo Pharma ( SILO ) said Tuesday that it has completed a pre-Investigational New Drug meeting with the US Food and Drug Administration to discuss the company's development plan for SPC-15, a potential treatment for post-traumatic stress disorder and stress-induced anxiety disorder.

The purpose of the meeting was for the company to coordinate with the FDA on a regulatory pathway for approval of SPC-15, Silo said.

Shares of the life sciences company were down more than 18% in recent Tuesday's premarket activity.

Price: 1.0100, Change: -0.22, Percent Change: -17.89